SCHEMBL30765670

SCHEMBL30765670

O=c1[nH]c(N2CCCCC2)cnc1Br

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TYMP P19971 5/20 0.44
DAO P14920 2/20 0.42
LMNA P02545 1/20 0.39
ALDH1A1 P00352 3/20 0.38
POLB P06746 2/20 0.38
MAPT P10636 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
IP6K1 Q92551 2/20 0.36
PKM P14618 1/20 0.36
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
HPGD P15428 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA4 P43681 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5365946 0.71 LMNA (0.40) DAOLMNAALDH1A1POLBMAPT
SCHEMBL5378266 0.68 LMNA (0.37) DAOLMNAALDH1A1POLBMAPT
SCHEMBL19051387 0.65 AR (0.35) TYMPMEN1CYP1A2CYP2C19KMT2A
SCHEMBL5378526 0.64 NPY5R (0.49) ALDH1A1MAPTKMT2AHPGD
SCHEMBL21388796 0.62 HPGD (0.47) ALDH1A1POLBMAPTPKMMEN1
SCHEMBL5383007 0.62 NPY5R (0.50) ALDH1A1MAPTKMT2AHPGD
SCHEMBL13813416 0.62 MAPT (0.41) TYMPALDH1A1POLBMAPTKDM4C
SCHEMBL31547605 0.61 KDM4E (0.44) DAOLMNAALDH1A1POLBMAPT
SCHEMBL21398887 0.60 KDM4E (0.44) LMNAALDH1A1POLBMAPTKDM4C
SCHEMBL4433604 0.60 POLB (0.42) LMNAALDH1A1POLBMAPTKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed